<DOC>
	<DOCNO>NCT02770040</DOCNO>
	<brief_summary>The purpose study identify whether Accelerated Intensified Infliximab induction regimen superior Standard induction Acute Severe Ulcerative Colitis open label multi-centre randomise control trial .</brief_summary>
	<brief_title>Optimising Infliximab Induction Therapy Acute Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Age &gt; 18 year old Diagnosis Ulcerative Colitis Acute Severe Colitis accord Truelove Witt 's Criteria Steroid refractory accord Oxford Criteria Participant unable consent Indication immediate surgery ( acute abdomen , perforation bowel , haemorrhage ) Crohn 's disease Participants enteric infection confirm stool microscopy , culture toxin Haemodynamic instability ( mean arterial pressure &lt; 60 ) responsive fluid Participants clinically significant Cytomegalovirus infection ( positive inclusion body , immunohistochemistry sign viraemia fever abnormal liver function test ) Participants pregnant currently breastfeed Participants current malignancy , exclude basal cell carcinoma Participants flat low high grade colonic dysplasia ; sporadic adenoma permit Participants serious comorbidities include : Immunodeficiency ; Myocardial infarction acute stroke within last 3 month ; Moderate severe heart failure ( New York Heart Association class III IV ) ; Active suspect tuberculosis ; Renal failure ; Hepatic failure ; severe infection Participants history hypersensitivity infliximab infliximab biosimilar Participants receive immunosuppressive agent include limited : AntiTNF therapy within 3 month screen ( Infliximab , Infliximab biosimilar , Golimumab , Etanercept , Certolizumab Adalimumab ) ; Antiintegrins ( Vedolizumb , Etrolizumab ) within 4 month screen ; Calcineurin inhibitor ( Cyclosporine , Tacrolimus ) within 4 week screen ; T B cell depleters ( Rituximab , Alemtuzumab ) within 12 month screen ; investigational agent ( eg . Ustekinumab ) within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Acute Severe Ulcerative Colitis</keyword>
	<keyword>Steroid Refractory Ulcerative Colitis</keyword>
</DOC>